• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Moringa Acquisition Corp Files its Annual Report for the 2021 Year

    4/5/22 7:33:44 AM ET
    $MACA
    Blank Checks
    Finance
    Get the next $MACA alert in real time by email

    NEW YORK, NY, April 05, 2022 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NasdaqCM: MACA, MACAU and MACAW) (the "Company") announced that it filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission on March 31, 2022. Copies of the annual report and other filings are available online through the Company's website, https://www.moringaac.com/, or by accessing the Securities and Exchange Commission's website, www.sec.gov. Copies may also be obtained from the Company, Attn: Gil Maman, 250 Park Avenue, 7th Floor, New York, NY 11040, or by email: [email protected].

    About Moringa Acquisition Corp

    Moringa Acquisition Corp was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company has been focusing on Israel-related technology companies.

    Forward-Looking Statements

    This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company's management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company's filings with the Securities and Exchange Commission ("SEC"). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's annual report filed with the SEC. Copies of that and other filings are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Contact:

    Moringa Acquisition Corp

    Gil Maman – [email protected]



    Get the next $MACA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MACA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MACA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

      Report covers Silexion Therapeutics (NASDAQ:SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company's impressive clinical achievements and unique approach alongside industry drivers including the increasing M&A activity in the space Silexion Therapeutics (NASDAQ:SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ:MACA), Silexion presents an interesting opportunity in the rap

      9/9/24 7:32:00 AM ET
      $MACA
      $SLXN
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

      MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd. ("Silexion"), a clinical-stage, oncology-focused biotechnology company and Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination") with Biomotion Sciences (the "combined company"), a recently formed entity. The combined company's name is changing from Biomotion Sciences to "Silexion Therapeutics Corp", and its ordinary shares and warrants are expected to begin trading on Nasdaq under the tickers "SLXN" and "SLXNW", respectively, on August 16

      8/15/24 4:05:00 PM ET
      $MACA
      Blank Checks
      Finance
    • Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

                                             Silexion's first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi'in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. ("Silexion"), a cli

      2/22/24 8:27:00 AM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance

    $MACA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/14/24 6:28:12 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/12/24 4:24:57 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/8/24 1:16:56 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Moringa Acquisition Corp

      SCHEDULE 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      8/27/24 11:00:41 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 15-12G filed by Moringa Acquisition Corp

      15-12G - Moringa Acquisition Corp (0001835416) (Filer)

      8/26/24 9:49:09 AM ET
      $MACA
      Blank Checks
      Finance
    • Moringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Moringa Acquisition Corp (0001835416) (Filer)

      8/21/24 4:05:08 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Hudson Bay Capital Management Lp disposed of $4,253,473 worth of Class A Ordinary Shares (401,271 units at $10.60)

      4 - Moringa Acquisition Corp (0001835416) (Issuer)

      8/24/23 2:31:41 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 3: New insider Hudson Bay Capital Management Lp claimed ownership of 401,271 units of Class A Ordinary Shares

      3 - Moringa Acquisition Corp (0001835416) (Issuer)

      4/5/23 4:59:51 PM ET
      $MACA
      Blank Checks
      Finance